High materiality7/10
Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
CGEM price target raised to $27 at UBS; current price around $20.76.
- CGEM PT to $27; price ~ $20.76
- UBS sees upside; target above current price
Key facts
- 01
Target: $27
- 02
Posted price: $20.76
- 03
Analyst firm: UBS
- 04
Analyst: David Dai
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.